Granted Patent
B2
US 12,006,322 · App. 18/471,250 · Granted Jun 11, 2024
Substituted pyridines as PARP1 inhibitors
Inventors:
Robert L. Hoffman (San Diego, CA); Porino Jinjo Va (San Diego, CA); Joseph Robert Pinchman (San Diego, CA); Qing Dong (San Diego, CA); Stephen W. Kaldor (San Diego, CA)
Assignee:
Xin Thera, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer and are of Formula (Ip):
Claims (5)
1. A compound:
or a pharmaceutically acceptable salt or tautomer thereof.
2. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound of claim 1 , or a pharmaceutically acceptable salt or tautomer thereof.
3. A compound:
4. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound of claim 3 .
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 29, 2024
From: KALDOR, STEPHEN W.
To: XINTHERA, INC.
Reel/Frame 066279/0082 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 29, 2024
From: HOFFMAN, ROBERT L.; VA, PORINO JINJO; PINCHMAN, JOSEPH ROBERT; DONG, QING
To: XINTHERA, INC.
Reel/Frame 066279/0144 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 26, 2024
From: HOFFMAN, ROBERT L.; VA, PORINO JINJO; PINCHMAN, JOSEPH ROBERT; DONG, QING
To: XINTHERA, INC.
Reel/Frame 066260/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 26, 2024
From: KALDOR, STEPHEN W.
To: XINTHERA, INC.
Reel/Frame 066375/0769 →
Continuity (5)
Continuation
18449569
· Aug 14, 2023
Provisional Application
63336078
· Apr 28, 2022
Provisional Application
63381482
· Oct 28, 2022
Cited By (2)